Clomipramine concentration as a predictor of delayed response: a naturalistic study M. Gex-FabryA. E. Balant-GorgiaL. P. Balant CLINICAL TRIALS Pages: 895 - 902
The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment T. KorhonenM. L. HannukselaM. J. Savolainen PHARMACODYNAMICS Pages: 903 - 910
Cytosolic calcium and lymphoproliferative response during calcium antagonism in men P. LijnenR. FagardV. Petrov PHARMACODYNAMICS Pages: 911 - 915
Topical heparin for the treatment of acute superficial phlebitis secondary to indwelling intravenous catheter A double-blind, randomized, placebo-controlled trial M. VillardellD. SabatC. Vallvé PHARMACODYNAMICS Pages: 917 - 921
Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects C. LaroudieD. E. SalazarJ.-P. Decourt PHARMACOKINETICS AND DISPOSITION Pages: 923 - 928
The oral bioavailability of pentosan polysulphate sodium in healthy volunteers R. A. FaaijN. SrivastavaA. F. Cohen PHARMACOKINETICS AND DISPOSITION Pages: 929 - 935
Plasma esterases in cystic fibrosis: the impact of a respiratory exacerbation and its treatment K. Abou-HatabL. S. NixonK. W. Woodhouse PHARMACOKINETICS AND DISPOSITION Pages: 937 - 941
Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance O. SpigsetS. HäggR. Dahlqvist PHARMACOKINETICS AND DISPOSITION Pages: 943 - 946
Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes A. HemeryckC. De VriendtF. M. Belpaire PHARMACOKINETICS AND DISPOSITION Pages: 947 - 951
Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function H. ButerG. Y. NavisP. E. de Jong PHARMACOKINETICS AND DISPOSITION Pages: 953 - 958
Suspected adverse drug events requiring emergency department visits or hospital admissions R. RaschettiM. MorguttiC. La Guidara PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 959 - 963
Use of laxatives in institutions for the mentally retarded M. Van WinckelR. Vander SticheleM. Bogaert PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 965 - 969